The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

PURPOSE: mutations are among the most common recurrent alterations in non-small cell lung cancer (NSCLC), but the relationship to other genomic abnormalities and clinical impact has not been established. EXPERIMENTAL DESIGN: alterations treated at Memorial Sloan Kettering. RESULTS: = 0.027). CONCLUSIONS: -mutant lung cancers may be more sensitive to immunotherapy.